Company Analysis

Q/C Technologies, Inc. (QCLS)

Nasdaq: QCLS · In Vitro & In Vivo Diagnostic Substances · New York, NY · filing with the SEC since 2005
Grade3.1
◀ Past 1.3● Present 2.5▶ Future 4.7
3 est.

Who runs Q/C Technologies, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Officers reporting now
5
of 9 people with a filing in the last fifteen months
Directors reporting now
4
24 people on the record since 2014
Officerssales are open-market, Oct 2, 2025 to Oct 2, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Silverman JoshuaExecutive ChairmanSep 2018Oct 2, 2026none
Ehrlichman YossefChief Technology OfficerSep 2026Sep 22, 2026none
Fagan Charles ToddChief Financial OfficerAug 2026Aug 17, 2026none
Glass MitchellChief Medical OfficerMay 2024Apr 15, 2026none
Rauch Gary MVP - Finance, TreasurerJan 2014Nov 14, 2025none
Directorssales are open-market, Oct 2, 2025 to Oct 2, 2026
NameRoleFirst filingLatest filingSales, 12 months
Voss Chelsea SierradirectorJan 2026May 14, 2026none
Bernstein BrucedirectorOct 2025Apr 15, 2026none
Friscia StephendirectorJun 2024Apr 15, 2026none
White Billy JoedirectorApr 2018Apr 15, 2026none
Owners of more than 10% of a classsales are open-market, Oct 2, 2025 to Oct 2, 2026
NameRoleFirst filingLatest filingSales, 12 months
Pharmacyte Biotech, Inc.10% ownerMay 2024Nov 18, 2025none
Earlier names on the record18, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton QCLS · research, not advice